Investing.com - Brainstorm Cell Therapeutics (NASDAQ:BCLI) reported on Monday third quarter earnings that missed analysts' forecasts and revenue that was in line with expectations.
Brainstorm Cell Therapeutics announced earnings per share of $-0.530 on revenue of $0.00. Analysts polled by Investing.com anticipated EPS of $-0.180 on revenue of $0.
Brainstorm Cell Therapeutics shares are down 45% from the beginning of the year, still down 62.55% from its 52 week high of $4.70 set on August 15.
Brainstorm Cell Therapeutics shares gained 15.79% in intra-day trade following the report.
Brainstorm Cell Therapeutics follows other major Healthcare sector earnings this month
Brainstorm Cell Therapeutics's report follows an earnings beat by J&J on October 18, who reported EPS of $2.55 on revenue of $23.79B, compared to forecasts EPS of $2.48 on revenue of $23.36B.
Eli Lilly had beat expectations on November 1 with third quarter EPS of $1.98 on revenue of $6.94B, compared to forecast for EPS of $1.91 on revenue of $6.91B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar